TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07218146: A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer

Sponsor: Zai Lab (Shanghai) Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 480 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT07218146 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07218146 Rescue Dossier →